

## FACSIMILE

Date: April 5, 2001

From: Harry B. Shubin

To: Examiner F. Higel  
U.S. PATENT AND TRADEMARK  
OFFICE  
Group Art Unit 1626

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.  
Arlington Courthouse Plaza I  
2200 Clarendon Blvd., Suite 1400  
Arlington, VA 22201 (U.S.A.)  
(Fax: 703-243-6410)

Facsimile No.: (703) 308-7921

Writer's Direct Dial: (703) 812-5306

Telephone No.:

Writer's Internet Address: shubinh@mwzb.com

RE: U.S. Patent Application Serial No. 09/755,060  
Attorney Docker No. BAYER-1 D1

Total No. of Pages: 18; if you do not receive all pages, please call 703-243-6333.

Dear Examiner Higel:

Attached is a copy of the Preliminary Amendment submitted in the above-referenced application on January 8, 2001. This copy is being provided at your request.

Very truly yours,



Nancy J. Robins  
Secretary to Harry B. Shubin

HBS:njr  
Attachment

K:\PAT\Bayer\1 D1\fax to Examiner 04.05.01.wpd

Information contained in this facsimile communication may contain privileged and confidential information and is intended solely for the use of the addressee listed above. If you are neither the intended recipient nor the employee or agent responsible for delivering this communication to the intended recipient, you are hereby notified that any disclosure, copying or distribution of, or the taking of any action in reliance on the contents of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone on (703) 243-6333 to arrange for return of the original documents to us at our cost. Thank you.

3/8

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Box: PATENT APPLICATION

Jill E. WOOD et al.

Group Art Unit: 1626

Serial No. Div. of 09/083,399

Examiner: F. Higel

Filed: December 14, 2000

For: RAF KINASE INHIBITORS

PRELIMINARY AMENDMENTCommissioner for Patents  
Washington, D.C. 20231

Sir:

Please amend the above-identified application as follows prior to calculation of the fees.

In the Claims:

Cancel claims 1 to 18 without prejudice or disclaimer.

Amend the claims as follows:

19. A method for the treatment of cancerous cell growth mediated by raf kinase, comprising administering a compound of the formulae:

